Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug

K.D. Smith, S. Paterson

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
55 Downloads (Pure)


Imatinib mesylate (Glivec®, Novartis Pharma) is a highlyefficacious tyrosine kinase inhibitor, designed for treatment of chronic myeloid leukaemia (CML), by virtue of its ability to inhibit the oncogenic signalling of the BCR-ABL protein
believed to be the causative abnormality of the disease. However, resistance is observed in a subset of CML patients, which could be due to mutations in BCR-ABL that prohibit binding of imatinib or overexpression of the BCR-ABL gene
(Paterson et al, 2003). Alternatively, circulating serum proteins have been proposed as an alternative mechanism that reduces imatinib efficacy through non specific binding to the drug. In particular, it has been suggested that the protein a-1-acid glycoprotein (AGP) can bind to imatinib in the plasma and hence decrease the free, and therefore active, concentration of the drug (Gambacorti-Passerini et al, 2000).
Original languageEnglish
Pages (from-to)9-10
Number of pages2
Publication statusPublished - Nov 2005


  • pharmaceutical
  • materia medica


Dive into the research topics of 'Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug'. Together they form a unique fingerprint.

Cite this